Read more

June 20, 2024
1 min watch
Save

VIDEO: Dual Ang-2, VEGF inhibition provides clinical benefits

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Patricio Schlottmann, MD, discusses dual inhibition of the Ang-2 and VEGF pathways.

Schlottman, of the Organización Médica de Investigación in Buenos Aires, Argentina, said dual inhibition with agents such as faricimab has the potential to provide clinical benefits such as reduced leakage, inflammation and fibrosis regardless of the anti-VEGF dose.

“When you treat a patient aiming for a dual blockage with taking care of the angiopoietin pathway and also blocking the VEGF pathway, you may see more clinical benefit than just treating your patients by blocking the anti-VEGF pathway,” he said.